Sustained virologic response after 6 weeks of therapy with a first-generation hepatitis C virus protease inhibitor

Clin Infect Dis. 2014 May;58(9):1342-4. doi: 10.1093/cid/ciu070. Epub 2014 Feb 5.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / administration & dosage
  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use*
  • Drug Therapy, Combination / adverse effects
  • Female
  • Hepacivirus / genetics
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Middle Aged
  • Oligopeptides / administration & dosage
  • Oligopeptides / adverse effects
  • Oligopeptides / therapeutic use*
  • Protease Inhibitors / administration & dosage
  • Protease Inhibitors / adverse effects
  • Protease Inhibitors / therapeutic use*

Substances

  • Antiviral Agents
  • Oligopeptides
  • Protease Inhibitors
  • telaprevir